Vimarsana
Biggest News Aggregation in the World

Thomas Prevoznik News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thomas Prevoznik. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thomas Prevoznik Today - Breaking & Trending Today

DEA Extends Flexibilities for Telemedicine Prescriptions - Vimarsana News

DEA Extends Flexibilities for Telemedicine Prescriptions

The Drug Enforcement Agency released Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. They have extended COVID-19 waivers for prescribing controlled substances via telemedicine until November 11, 2023.

Two Cancer Patients Battle to Make Psilocybin Accessible for Palliative Care - Vimarsana News

Two Cancer Patients Battle to Make Psilocybin Accessible for Palliative Care

Their efforts could benefit countless others in need of an end-of-life measure

DEA, federal law give pharmaceutical companies the lead in tracing suspicious opioid orders - Vimarsana News

DEA, federal law give pharmaceutical companies the lead in tracing suspicious opioid orders

CHARLESTON — Opioid manufacturers’ compliance with the federal Controlled Substances Act depended heavily on the judgment, diligence and action of compliance executives and other employees at those companies, according to

Defense attorneys question DEA official about opioid suspicious orders in West Virginia trial - Vimarsana News

Defense attorneys question DEA official about opioid suspicious orders in West Virginia trial

CHARLESTON — An official of the U.S. Drug Enforcement Administration told attorneys defending suppliers of opioid drugs that the companies were supposed to protect against suspicious drug orders without specific guidance from the DEA.

DEA, federal law give pharmaceutical companies the lead in tracing suspicious opioid orders - Vimarsana News

DEA, federal law give pharmaceutical companies the lead in tracing suspicious opioid orders

CHARLESTON — Opioid manufacturers’ compliance with the federal Controlled Substances Act depended heavily on the judgment, diligence and action of compliance executives and other employees at those companies, according to